PM Tracker

CMS has finalized a rule that indefinitely delayed a controversial alternative payment model surrounding radiation oncology after Congress instituted multiple delays.

In an unfortunate series of events reminiscent of those that led to the discontinuation of the HeartWare Ventricular Assist Device last year, Medtronic has now racked up a third Class I recall for the heart pump since taking it off the market.

By the end of 2023, Novartis plans to shutter its Sandoz oral solid dosage plant in Wilson, North Carolina, where the company’s soon-to-be-spun-off generics division makes products like tablets and capsules for Canada and the U.S. The site’s roughly 246 employees have already been alerted to the closure, the company said.

Kerry Blanchard has resigned as CEO of Everest Medicines with immediate effect. While the Chinese drug developer only shared the news on Thursday evening, it has spent the past few months searching for a CEO, putting it on course to appoint a successor to Blanchard in the coming month.

July 2022's annual urban consumer price changes for healthcare and the broader economy were 4.8% and 8.5%, respectively, potentially opening the door to greater price increases among providers and payers in the coming years, analysts wrote Wednesday.

About four months after beginning its hunt for a new CEO to replace Don Casey—and amid an ongoing investigation into past financial practices—Dentsply Sirona’s search is complete.

This week on "The Top Line," we discuss Genentech’s Greg Rippon's remarks on missing the mark in terms of diverse trial recruitment and how the company hopes to get it right in the future. We'll also chat about a new report on brand awareness for diabetes drugs.

The Association of Clinical Research Organizations (ACRO) is stepping up its efforts to address the age-old problem of the lack of diversity in clinical trial populations. With its principles statement, the trade group has set out what its members will do to make clinical trials—and their own workforces—more diverse.

Virtual health is here to stay following a massive increase in use during the pandemic, but employers believe that it needs to evolve, a new survey shows.

Designed to work with available point-of-care ultrasound machines, UltraSight's AI assists technicians in navigating a probe regardless of their previous experience.

An anticipated merger between Merck and Seagen has stalled because the companies can’t agree on a price, Bloomberg reports. The potential deal—which was rumored to be valued at around $40 billion—remains on the table and could still happen soon, the new outlet reports.

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Advanced research requires advanced tools. Our next-generation ELISA takes a fraction of the time to run eight analytes simultaneously while saving your sample volume. Simply load, scan, and insert your cartridge and come back to fully analyzed results in 75 minutes. Rethink your ELISA, with Ella.

Set a solid foundation for successful scale-up of buffer preparation.

The TrialCard/Triangle Insights Group platform is uniquely positioned to support you as your asset progresses through the value chain, by integrating strategic commercialization and market access insights with comprehensive patient and provider support services.

See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead.

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

What are key considerations for intranasal delivery in the treatment of acute and chronic conditions?

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry.

Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays?

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.